Primary Care Exercise Counseling Cost-Effective for Older Men

Share this content:
Primary Care Exercise Counseling Cost-Effective for Older Men
Primary Care Exercise Counseling Cost-Effective for Older Men

WEDNESDAY, Feb. 8, 2017 (HealthDay News) -- For older male veterans, improvements in physical activity and rapid gait speed can be obtained at a relatively low cost relative to patient annual health care costs, according to a study published online Feb. 2 in the Journal of the American Geriatrics Society.

Patricia A. Cowper, Ph.D., from the Duke Clinical Research Institute in Durham, N.C., and colleagues conducted an economic assessment of a primary care-based physical activity counseling intervention that improved physical activity levels and rapid gait speed in 398 older male veterans (aged ≥70 years). Intervention costs were examined, and health care resource use and costs were estimated through one year of follow-up.

The researchers found that per participant, the total direct cost of the intervention was $459; 85 percent of which was counselor effort. Program cost totaled $696 per participant with overhead. During follow-up, medical costs reached $10,418 with the intervention, compared with $12,052 with usual care (difference, −$1,634; 95 percent confidence interval, −$4,683 to $1,416; P = 0.29). In terms of short-term clinical outcomes, the intervention cost $4,971 or $4,640 per additional patient reaching the target exercise level or per patient achieving a clinically significant change in rapid gait speed, respectively.

"Improvements in physical activity and rapid gait speed in the physical activity counseling group were obtained at a cost that represents a small fraction of patients' annual health care costs," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »